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24Objective: This study aimed at retrospectively evaluating the outcomes of radiofrequency ablation of clinical
stage I non–small cell lung cancer.
Methods: This study was carried out on 50 nonsurgical candidates (29 men and 21 women; mean age, 74.7
years) with clinical stage I (IA, n ¼ 38; IB, n ¼ 12) histologically proven non–small cell lung cancer. A total
of 52 tumors were treated with 52 ablation sessions. Radiofrequency ablation was performed percutaneously
under computed tomography fluoroscopic guidance. The outcomes of radiofrequency ablation were evaluated,
including toxicity, local efficacy, and patient survival. Toxicity was evaluated using the National Cancer Institute
Common Terminology Criteria for Adverse Events Version 4.0. Local efficacy was evaluated by using computed
tomography scan with a contrast medium. The overall, cancer-specific, and disease-free survivals were esti-
mated with Kaplan–Meier analysis.
Results: Grade 2 and 3 adverse events occurred after 6 (12%) and 3 (6%) of the 52 sessions, respectively. The
median follow-up period was 37 months. Local progression was observed in 16 (31%) of the 52 tumors. The
median survival time was 67 months. The overall, cancer-specific, and disease-free survivals were 94%,
100%, and 82% at 1 year, 86%, 93%, and 64% at 2 years, and 74%, 80%, and 53% at 3 years, respectively.
Conclusions:Radiofrequency ablation of clinical stage I non–small cell lung cancer was minimally invasive and
provided promising patient survival, although the local efficacy needs to be improved. (J Thorac Cardiovasc
Surg 2011;142:24-30)Primary lung cancer is the most common malignancy and
the leading cause of death from cancer worldwide. Surgical
resection with a lobectomy is suggested as the first-line
treatment for treating early-stage non–small cell lung can-
cer (NSCLC). Unfortunately, certain patients are consid-
ered medically inoperable, and conventional external
beam radiation therapy (XRT) has been traditionally admin-
istered to such patients. A meta-analysis of patients with
stage I NSCLC treated by conventional XRT revealed
mean overall and cause-specific survivals at 3 years of
34% and 39%, respectively.1 Because such survival out-
comes after XRTare unsatisfactory, various alternative mo-
dalities have been the focus of many studies. For example,
stereotactic radiation therapy shows favorable survivals for
patients with stage I NSCLC: 56% to 60% at 3 years.2-4
Radiofrequency ablation (RFA) has received considerable
attention as a local therapy mainly for hepatic cancer. Thee Department of Radiologya and Cancer and Thoracic Surgery,b Okayama
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The Journal of Thoracic and Cardiovascular Surgefavorable outcomes of RF ablation of hepatic cancer have
facilitated the application of this technique to lung cancer.
Currently, RFA is gaining popularity as a treatment of
lung cancer. The purpose of this study was to
retrospectively evaluate the outcomes of RFA on
nonsurgical candidates with clinical stage I NSCLC.MATERIALS AND METHODS
Study Population
Approval from the institutional review board and informed consent
from the patients were obtained to perform RFA of lung cancer. Our insti-
tutional review board also provided approval for our retrospective study.
From July 2002 to September 2009, we treated 56 patients with clinical
stage I primary lung cancer at OkayamaUniversityMedical School.We ex-
cluded 6 of these patients, because the tumor was also treated with adjuvant
radiation therapy (n ¼ 4), the patient was lost to follow-up (n ¼ 1), or the
tumor was not histologically proven (n ¼ 1). Thus, this study consisted of
50 patients with histologically proven clinical stage I NSCLC. Twenty pa-
tients who were previously reported in the literature5 were included in this
study, although their follow-up information was updated. Two patients had
synchronous double primary lung cancers; thus, a total of 52 tumors were
treated with 52 ablation sessions.
For clinical staging, chest and abdomen computed tomography (CT)
scans were performed in all patients; positron emission tomography
(PET) scanning was performed in 29 patients, and brain magnetic reso-
nance imaging was performed in 26 patients. Lymph node metastasis
was considered absent, because none of the lymph nodes were larger
than 1.0 cm in short-axis diameter and there was no more accumulation
of 18F-fluorodeoxy glucose in the lymph nodes than mediastinal structures
when PETwas performed. This led to the diagnosis of clinical stage IA and
IB cancers in 38 and 12 patients, respectively.ry c July 2011
Abbreviations and Acronyms
CT ¼ computed tomography
NSCLC ¼ non–small cell lung cancer
PET ¼ positron emission tomography
RFA ¼ radiofrequency ablation
XRT ¼ external beam radiation therapy
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in Table 1. Therewere 29 men and 21 women (mean age, 74.7 years; range,
52–88 years). Sixteen patients had a history of surgery for the following
types of cancer: lung cancer (n¼ 9), esophageal cancer (n¼ 2), cholangio-
carcinoma (n ¼ 2), hepatocellular carcinoma and pulmonary metastasis
(n ¼ 1), breast cancer (n ¼ 1), and colon, uterus, and ureter cancer
(n ¼ 1). The mean long-axis tumor diameter was 2.1 cm (median, 1.8
cm; range, 0.7–6.0 cm). There were 41 adenocarcinomas and 11 squamous
cell carcinomas. Eleven tumors in 10 patients were adenocarcinomas show-
ing pure ground-glass opacity on CT images.
Patients were first referred to the department of thoracic surgery. All pa-
tients were determined to be nonsurgical candidates by a surgeon because of
one or more of the following reasons: poor pulmonary function (predicted
forced respiratory volume in 1 second  1000 mL), poor cardiac function
(New York Heart Association class  III), advanced age (80 years), poor
performance status (2), substantial comorbidity, or refusal to undergo sur-
gery. Fourteen patients had poor pulmonary function, 1 patient had poor car-
diac function, 7 patients had advanced age, 1 patient had poor performance
status, 7 patients had substantial comorbidity, and 9 patients had combina-
tions of 2 of those reasons. The remaining 11 patients were deemed operable
but refused to undergo surgery. For the 27 patients whose vital capacity was
examined before RFA, the mean value was 2.53 L (range, 1.06–3.97 L); for
the 30 patients whose forced expiratory volume and volume percentage in
1 second were examined before RFA, the mean values were 1.68 L (range,
0.41–3.19 L) and 68.6% (range, 42.3%–96.3%), respectively. No patient
received concurrent or adjuvant therapy.
Radiofrequency Ablation Technique
RFAwas always performed percutaneously using CT fluoroscopy (As-
teion; Toshiba, Tokyo, Japan). Intraprocedural pain was treated by using lo-
cal anesthesia or epidural anesthesia along with conscious sedation with an
intravenous drip infusion of 0.3 mg fentanyl and an intramuscular injection
of 25 mg hydroxyzine. In the case of expected severe procedural pain, for
example, when the tumor was close to the pleura, or if the patient asked for
it, epidural anesthesia was administered. Thus, epidural anesthesia was
used in 15 sessions (15 patients). General anesthesia was not used for
any of the patients.
Patients were placed in a supine or prone position according to the lo-
cation of the tumor, and grounding pads were placed on their thighs. An
initial CT examination was scanned to identify the precise location of the
tumor and decide the pathway of electrode insertion. The skin at the entry
site of the electrode was sterilized. After the administration of anesthesia,
the electrode was introduced into the tumor and connected to a generator.
The electrodes that were used for the ablation included a multitined ex-
pandable electrode (LeVeen; Boston Scientific, Natick,Mass) with an array
diameter of 2 cm (n¼ 15), 3 cm (n ¼ 15), 3.5 cm (n¼ 4), or 4 cm (n ¼ 2);
a single internally cooled electrode (Cool-tip; Valleylab, Boulder, Colo)
with a 1-cm (n ¼ 3), 2-cm (n ¼ 7), or 3-cm (n ¼ 4) noninsulated tip; or
a cluster internally cooled electrode (n ¼ 2) (Cool-tip; Valleylab). In the
case of the Valleylab device, radiofrequency energy was applied with an
impedance control algorithm for 12 minutes during the internal cooling
of the electrode. The temperature of the tumor at the electrode tip was mea-
sured immediately after the generator was turned off. When the tempera-The Journal of Thoracic and Cture failed to reach 60C, additional application at the same site was then
required. When using the Boston Scientific device, the energy was applied
until the impedance showed a rapid increase or an automatic shut-off oc-
curred after 15 minutes; this was repeated once at each site. To obtain
the ablative margin, multiple overlapping ablation zones were created
whenever deemed necessary.
A chest CT scanwas performed immediately after the procedure to eval-
uate ablation zone and procedural complications. A chest radiograph was
obtained 3 hours later and the following morning to assess the occurrence
of complications, such as pneumothorax, hemothorax, and pleural effusion.
A complete blood count and blood biochemistry were examined at 1 and 3
days after RFA.Follow-up
The patients were followed up, whenever possible, at 1, 3, 6, 9, and 12
months, and thereafter at 6-month intervals. At every follow-up session,
a chest CT scan was performed with 5-mm collimation before and 30
and 90 seconds after the intravenous administration of a contrast medium
(iopamidol, Iopamiron 300; Nihon Schering, Osaka, Japan) at a rate of 3
mL/s to assess local efficacy. The size of the ablated lesion usually exceeds
the preprocedural tumor size on CT images for the first 3 months after RFA,
because the ablated lesion is detected together with the ablated marginal
parenchyma.6 During this period, thus, the effectiveness of RF ablation
cannot be determined by comparing the tumor size but can be determined
by contrast enhancement. That is, the tumor is considered to be completely
treated when the entire ablation zone is not contrast-enhanced or when the
ablation zone exhibits contrast enhancement; however, the enhancement
zone is peripheral, concentric, symmetric, and uniform with smooth inner
margins. Such enhancement zone is considered to correspond to reactive
hyperemia, inflammation, or granulation at the marginal parenchyma.7
Thereafter, local efficacy was evaluated by comparing the size and geom-
etry of the ablation zone in the previous CT images. Local progression was
defined as tumor progression at the ablation zone and considered to have
occurred when the ablation zone was circumferentially enlarged or an ir-
regular, scattered, nodular, or eccentric focus in the ablation zone appeared.
The focus generally exhibited some degree of contrast enhancement, and
thus contrasted against the unenhanced necrotic tumor tissue.
For the assessment of hematogenous metastasis, an abdominal CT scan
was generally performed with a contrast medium at 6-month intervals. Al-
though PET was not included in our routine follow-up modalities, for 29
patients, PET examinations were also performed to evaluate the outcomes
of RFA and hematogenous metastasis.When symptoms suggesting brain or
bone metastasis were observed, a radiologic examination such as magnetic
resonance imaging or a bone scintigram was performed.Study End Points and Statistical Analysis
The study end points included toxicity, local efficacy, and patient sur-
vival. Toxicity was evaluated using the National Cancer Institute Common
TerminologyCriteria for Adverse Events Version 4.0, and adverse events of
grade greater than 1 were noted. The forced expiratory volume in 1 second
1 to 3 months after RFAwas compared with that before RFA by using the
paired t test. Local efficacy was evaluated by the presence of local tumor
progression, which was diagnosed with the aforementioned criteria. The
overall local progression rates and the local progression rates according
to tumor sizewere calculated. Further, the local progression rates according
to type of electrode used (internally cooled electrode or multitined expand-
able electrode) were compared by using the log-rank test. In addition to lo-
cal progression, parenchymal recurrence (defined as recurrence in the same
lobe but away from ablation zone), regional recurrence (defined as hilar and
ipsilateral mediastinal lymph nodes recurrence), and distant recurrence (all
other recurrences) were also evaluated.
The overall, cancer-specific, and disease-free survivals were estimated
with Kaplan–Meier analysis. For estimation of cancer-specific survivalardiovascular Surgery c Volume 142, Number 1 25
TABLE 1. Characteristics of the 50 patients and the 52 tumors
Patients (n ¼ 50)
Age (y)
Mean 74.7
Range 52–88
Gender
Male 29
Female 21
Vital capacity (L)*
Mean 2.53
Range 1.06–3.97
Forced expiratory volume in 1.0 s (L)y
Mean 1.68
Range 0.41–3.19
Stage
IA 38
IB 12
History of surgery for cancer
Yes 16
No 34
Tumors (n ¼ 52)
Diameter (cm)
Mean 2.1
Range 0.7–6.0
Histology
Adenocarcinoma 41
Squamous cell carcinoma 11
Lobar location
RUL/RML/RLL 10/2/12
LUL/LLL 15/13
Electrode used for ablation
Internally cooled 16
Multitined expandable 36
RUL, Right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left up-
per lobe; LLL, left lower lobe. *Data are available in 27 patients. yData are available
in 30 patients.
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any death or cancer recurrence, respectively. The survivals were also esti-
mated according to cancer stage (IA or IB), type of electrode used, and pro-
cedure period (first 4 years or later years), and compared between the 2
groups by using the log-rank test. Statistical analyses were performed using
the Statistical Package for the Social Sciences software (version 11.0;
SPSS Inc, Chicago, IL).RESULTS
The case of a 79-year-old woman with clinical stage IA
NSCLC is shown in Figure 1. Grade 1 pneumothorax
occurred after 22 sessions. Grade 2 and 3 adverse events oc-
curred after 6 (12%) and 3 (6%) of the 52 sessions, respec-
tively, whereas no grade 4 or 5 adverse events occurred. The
grade 2 adverse events included pneumothorax that re-
quired chest tube placement after 1 session, pneumonitis
that required medical therapy after 3 sessions, and both of
those after 2 sessions. The grade 3 adverse events included
pleural effusion that required chest tube placement after 1
session, bronchopleural fistula that required surgical inter-26 The Journal of Thoracic and Cardiovascular Surgevention to cover the pleural orifice of the fistula in 1 session,
and pleural infection that required radiologic chest tube
placement after 1 session.
Among the 30 patients in whom forced expiratory vol-
ume in 1 second was examined before RFA, this test was re-
peated 1 to 3 months after RFA in 22 patients. The mean
forced expiratory volume in 1 second after RFA for the 22
patients was 1.58 L (range, 0.68–2.74 L); the volume was
not significantly different (P ¼ .17) than the volume before
RFA. Local progression was observed in 16 (31%) of the 52
tumors at a median of 15 months after the session. Five of
the 16 locally progressing tumors were confirmed by bi-
opsy. The local progression rate according to tumor size
was 33% (10/30) for tumors 2.0 cm or less, 40% (4/10)
for tumors 2.1 to 3.0 cm, and 17% (2/12) for tumors greater
than 3.0 cm. The local progression rates were not signifi-
cantly different according to type of electrode (P ¼ .10).
Six of the 16 locally progressing tumors were treated again
in 1 or 2 repeat sessions; 4 tumors were completely treated
and the other 2 tumors progressed again. Finally, local con-
trol was achieved in 40 (77%) of the 52 tumors at the time
of this report. Regional, parenchymal, and distant recur-
rence occurred in 2, 7, and 8 patients, respectively.
The median follow-up period of the 50 patients was 37
months (mean, 39 months; range, 2–88 months). The sur-
vival outcomes of the 50 patients are summarized in
Figure 2. Of the 50 patients, 19 died and 31 were surviving
at the time of this report. Of the 19 patients who died, 12
died of cancer progression and the remaining 7 died of other
causes. Of the 7 patients who died of other causes, 2 had lo-
cal progression and 5 were free from cancer. Of the 31 pa-
tients who survived, 20 were free from cancer since RFA.
Local progression or intrapulmonary metastasis developed
in 5 patients, who were then completely treated with a par-
tial resection or repeat RFA. At the time of this report, these
5 patients were free from cancer. The remaining 6 patients
showed recurrence, such as local progression, intrapulmo-
nary metastasis, or lymph node metastasis.
The median and mean survival times were 67 months and
59months, respectively. The overall survivals were 94% at 1
year, 86% at 2 years, 74% at 3 years, 67% at 4 years, and
61% at 5 years (Figure 3). The survivals for stage IA and
IB cancers were 95% and 92% at 1 year, 89% and 75% at
2 years, 83% and 50% at 3 years, 73% and 50% at 4 years,
and 66% and 50% at 5 years, respectively (Figure 4). The
survivals were not significantly different between the 2
groups (P ¼ .057). The survivals were not significantly
different according to type of electrode (P ¼ .35) or proce-
dure period (P ¼ .77). The cancer-specific survivals were
100% at 1 year, 93% at 2 years, 80% at 3 years, 80% at 4
years, and 74% at 5 years (Figure 3). The disease-free
survivalswere 82% at 1 year, 64% at 2 years, 53% at 3 years,
46% at 4 years, and 46% at 5 years (Figure 3). The median
and mean disease-free survival times were both 42 months.ry c July 2011
FIGURE 1. RFA for a 79-year-old woman with clinical stage IA NSCLC. A, CT image before the procedure shows a tumor (arrow) of 29 mm in maximum
diameter in the left upper lobe. B, PET/CT image before the procedure shows marked accumulation of 18F-fluorodeoxy glucose into the tumor (arrow). C,
CT-fluoroscopic image during the procedure shows that a multitined expandable electrode (arrows) is introduced into the tumor. D, PET/CT image 3months
after the procedure shows no obvious accumulation of 18F-fluorodeoxy glucose into the tumor (arrow). E, CT image 31 months after the procedure shows
considerable tumor involution (arrow).
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RFA is increasingly being used as an alternative local
therapy for nonsurgical candidates with lung cancer. A pro-
spective multicenter study of RFA on 106 patients with pri-
mary or secondary lung cancer noted technical success in
99% of patients and no procedural-related deaths.8 An in-
ternational survey reported that mortality after RFA of
lung tumors was 0.4%.9 Our study also confirmed that
RFA was a safe procedure with no mortality, only a 6%
grade 3 adverse event rate, and no significant effect on pul-
monary function.The Journal of Thoracic and CThe local progression rates and survival data after RFA of
clinical stage I NSCLC in the literature are summarized in
Table 2. Approximately 30% to 40% of the treated tumors
progressed locally,10-13 which was also observed in our
study. A number of studies showed that local efficacy
depends on tumor size, that is, larger tumors are at
a higher risk of local recurrence.10,13-15 In our study,
however, the local progression rate did not seem to
depend on tumor size. The exact reason for this
observation cannot be determined, but 3 groups divided
by their tumor size were heterogeneous in terms of theardiovascular Surgery c Volume 142, Number 1 27
FIGURE 2. Summary of survival outcomes of 50 patients with clinical stage I NSCLC treated with RFA. RFA, Radiofrequency ablation.
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was performed (ie, the issue of a learning curve), and the
follow-up period. These factors might bias the outcomes
of local efficacy according to tumor size. In view of the rel-
atively high local progression rate, the use of RFA should be
limited to patients who are inoperable or operable but refuse
to undergo surgery. Further, in the case of RFA, patients
should be followed frequently to find local progression as
early as possible.
The survivals after RFA of clinical stage I NSCLC were
reported as 78% to 100% at 1 year, 57% to 84% at 2 years,
and 36% to 74% at 3 years,8,10-14 and the overall survivals
in our study seem to be equivalent to these results. As
expected, the survival of patients with stage IA cancer
seemed to be better than the survival of patients withFIGURE 3. Overall survivals are 94% at 1 year, 86% at 2 years, 74% at 3
years, 67% at 4 years, and 61% at 5 years. The cancer-specific survivals
are 100% at 1 year, 93% at 2 years, 80% at 3 years, 80% at 4 years,
and 74% at 5 years. The disease-free survivals are 82% at 1 year, 64%
at 2 years, 53% at 3 years, 46% at 4 years, and 46% at 5 years.RFA,Radio-
frequency ablation.
28 The Journal of Thoracic and Cardiovascular Surgestage IB cancer, but this did not reach statistical
significance in our study, probably because of the small
size of the patient population. Although the overall and
cancer-specific survivals were promising, the disease-free
survival was limited to 53% at 3 years, mainly because of
the relatively high rate of local tumor progression. Further,
the promising overall and cancer-specific survivals may be
partly attributable to the relatively high rate (10/50, 20%) of
patients with pure ground-glass opacity adenocarcinoma,
which is slow-growing with a doubling time of more than
800 days.16,17
Stereotactic radiation therapy shows favorable local con-
trol and survivals for patients with stage I NSCLC, and may
rival RFA. According to a Japanese multi-institutional study
on the use of stereotactic radiation on 257 patients,2 theFIGURE 4. Survivals of stage IA and IB cancers are 95% and 92% at 1
year, 89% and 75% at 2 years, 83% and 50% at 3 years, 73% and 50% at
4 years, and 66% and 50% at 5 years, respectively. Survivals are not sig-
nificantly different between the 2 groups (P¼ .057). RFA, Radiofrequency
ablation.
ry c July 2011
TABLE 2. Summary of data by radiofrequency ablation of clinical stage I non–small cell lung cancer
Author
No. of
patients
Follow-up
period (mo)
Local progression
rate (%)
Survival (%) Survival
time (mo)1 y 2 y 3 y 4 y 5 y
Lencioni and colleagues8 13 75
Lee and colleagues10 10 14 (median) 40 100
Pennathur and colleagues11 19 29 (mean) 42 95 68
Hiraki and colleagues12 20 22 (median) 35 90 84 74 42 (mean)
Lanuti and colleagues13 31 17 (median) 32 85 78 47 47 30 (median)
Simon and colleagues14 75 78 57 36 27 27 29 (median)
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proportion of patients with local recurrence was 14%, and
the overall and cause-specific survivals were 57% and
77% at 3 years and 47% and 73% at 5 years, respectively.
A phase 2 North American multicenter study including 55
medically inoperative patients3 showed that the incidence
of adverse events for grade 3, 4, or 5 tumors was 13%,
4%, or 0%, respectively, the estimated 3-year primary tu-
mor control rate was 98%, and the disease-free and overall
survivals at 3 years were 48% and 56%, respectively. Ac-
cording to another multicenter prospective phase 2 trial in-
cluding 57 patients in Nordic countries,4 grade 3 and 4
toxicity occurred in 28% and 2% of the patients, respec-
tively, the estimated local control rate was 92% at 3 years,
and the overall, cancer-specific, and progression-free sur-
vivals were 60%, 88%, and 52% at 3 years, respectively.
In the future, it would be interesting to compare RFA with
stereotactic radiation therapy in a randomized controlled
study.
At Okayama University Medical School, stereotactic ra-
diation has been another available therapy for lung cancer.
Although selection of the 2 modalities may be difficult
sometimes because of the lack of data suggesting which is
better, roughly speaking, RFA is performed when perform-
ing stereotactic radiation seems hazardous, that is, when
a tumor is located near (<3 cm) the hilum, mediastinum,
lung apex, and vertebral body, and a tumor is located in
the lower lobe in patients with considerable respiratory mo-
tion. Given that stereotactic radiation seems more toxic
mainly because of radiation pneumonitis, RFA is apt to be
selected in patients with severe pulmonary dysfunction. In
contrast, considering the limited local efficacy of RFA, es-
pecially for tumors greater than 2 cm,15 such tumors are
likely to be treated with stereotactic radiation.
Notable advantages of RFA include its low invasiveness,
the preservation of pulmonary function, the freedom to per-
form the procedure regardless of any previous therapy, and
the ability to repeat the procedure whenever required. In
contrast, a substantial limitation of this procedure may be
its limited local efficacy. To secure favorable long-term
survival, the local efficacy needs to be improved. In animal
experiments, various attempts have been made to enhance
the efficacy of RFA. In the lung, thermal and electricalThe Journal of Thoracic and Cconductivities are limited because of alveolar air, and they
may be further limited by blood perfusion and ventilation.
Thus, successfully enlarged coagulation necrosis was
obtained by the modulation of conductivity by infusing sa-
line into the lung18 and decreasing blood perfusion19 and
ventilation.20
Combining RFAwith other therapies may enhance its ef-
fects. Dupuy and associates21 performed RFA followed by
conventional XRT in 24 patients with stage I cancer
(mean size, 3.4 cm). The local progression rate of 8%
seemed promising despite the relatively large tumor sizes.
The continuous evolution of the technology used in RFA
may aid in the development of this procedure. Navigation
devices that use electromagnetic tracking may facilitate
more accurate electrode insertion.22 In addition, other abla-
tive technologies, including microwave ablation and cryoa-
blation, are also being developed.23,24 Furthermore, a recent
study showed that RFA may be carried out by using
a transbronchoscopic approach.25Study Limitations
Our study had several limitations. This was a retrospec-
tive study with possible selection biases. We used 2 types
of ablation device, although a previous study indicated
that a multitined expandable electrode provided better local
efficacy than an internally cooled electrode.15 PETwas not
used for cancer staging in 21 patients, which may have af-
fected the reliability of clinical cancer staging. Finally,
the follow-up period was not long enough to determine
the long-term outcomes.CONCLUSIONS
RFA of clinical stage I NSCLC is minimally invasive and
provides promising patient survivals, although the local ef-
ficacy needs to be improved.References
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